Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists

A compound of Formula (I),

• or a pharmaceutically acceptable salt thereof wherein:
• R1 is a saturated 6-12 membered heterocyclic ring system containing 1 or 2 ring nitrogen atoms and an optional ring oxygen atom, which ring system incorporates spiro rings and which is attached to the pyridine ring via a nitrogen atom;
• R2 is selected from the group consisting of:
• hydrogen, C1-6alkyl, —C(O)NRaRb, —C(O)Ra, —SO2Ra, —C(O)ORa, oxo, —C(O)NRaRb, —NRaRb, —NRaC(O)Rb, —NRaC(O)ORb, and —NRaSO2Rb;
• Ra is selected from the group consisting of:
• hydrogen, C1-6alkyl, and C3-6cycloalkyl;
• Rb is selected from the group consisting of:
• hydrogen, C1-6alkyl, C3-6cycloalkyl, aryl, and heteroaryl;
• or Ra and Rb together with the nitrogen to which they are attached form a heterocycloalkyl, and said heterocycloalkyl is optionally substituted with one, two, or three Rc groups;
• R3 is H, F, Cl, C1-3alkyl, cyclopropyl, C1-3alkoxy, amino, C1-3alkylamino, oxo, or CN;
• Rc is H, F, Cl, C1-6alkyl, C3-6cycloalkyl, C1-3alkoxy, amino, C1-3alkylamino, oxo, or CN;
• X is (CH2)m;
• m is 0-2;
• n is 0-3;
• p is 0-3;
• with the proviso that R2 is not —NRaCOOH or —NRaSO2H.